ANI announced that the Food and Drug Administration (FDA) have approved its Abbreviated New Drug Application (ANDA) for nilutamide tablets, the generic version of Nilandron (Covis), indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer.

ANI will launch the product immediately, becoming the first-to-market generic of Nilandron. 

Related Articles

Nilutamide Tablets 150mg are available in a 30-count (3 cards x 10 tablets) size. 

For more information visit